ADMA BIOLOGICS, INC. (ADMA) Spending and interest coverage
- R&D / revenue · 12 months: Value 2.25%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.47%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2.25% | Research and development expense / revenue. Period ending 2026-06-30. $11.52M ÷ $512.27M × 100 ≈ 2.25% |
| Stock-based compensation / revenue · 12 months | 4.47% | Share-based compensation / revenue. Period ending 2026-06-30. $22.90M ÷ $512.27M × 100 ≈ 4.47% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 11.52M USD | Research and Development Expense |
| Revenue | 512.27M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 22.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 224.48M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.52M | $512.27M | $22.90M | $224.48M | (m) | 2.25% | 4.47% | (m) | (m) |
| 2026-03-31 | $6.53M | $509.86M | $21.73M | $214.84M | (m) | 1.28% | 4.26% | (m) | (m) |
| 2025-12-31 | $4.76M | $510.17M | $20.03M | $191.44M | (m) | 0.93% | 3.93% | (m) | (m) |
| 2025-09-30 | $3.78M | $488.56M | $20.07M | $167.01M | (m) | 0.77% | 4.11% | (m) | (m) |
| 2025-06-30 | $2.66M | $474.17M | $18.20M | $155.64M | (m) | 0.56% | 3.84% | (m) | (m) |
| 2025-03-31 | $2.19M | $459.38M | $16.10M | $152.04M | (m) | 0.48% | 3.50% | (m) | (m) |
| 2024-12-31 | $1.81M | $426.45M | $13.62M | $138.98M | (m) | 0.43% | 3.19% | (m) | (m) |
| 2024-09-30 | $1.87M | $382.81M | $9.93M | $114.89M | (m) | 0.49% | 2.59% | (m) | (m) |
| 2024-06-30 | $2.05M | $330.24M | $8.44M | $83.94M | (m) | 0.62% | 2.56% | (m) | (m) |
| 2024-03-31 | $2.90M | $283.18M | $7.22M | $44.27M | $22.68M | 1.02% | 2.55% | 1.95× | Reported |
| 2023-12-31 | $3.30M | $258.21M | $6.19M | $21.63M | $25.03M | 1.28% | 2.40% | 0.86× | Reported |
| 2023-09-30 | $3.93M | $234.29M | $5.51M | $1.34M | $24.55M | 1.68% | 2.35% | 0.05× | Reported |
| 2023-06-30 | $4.37M | $208.11M | $5.13M | $-16.66M | $23.73M | 2.10% | 2.46% | -0.70× | Reported |
| 2023-03-31 | $3.85M | $181.89M | $4.68M | $-25.36M | $22.01M | 2.11% | 2.57% | -1.15× | Reported |
| 2022-12-31 | $3.61M | $154.08M | $5.21M | $-39.37M | $19.28M | 2.35% | 3.38% | -2.04× | Reported |
| 2022-09-30 | $3.27M | $130.48M | $5.36M | $-46.50M | $16.86M | 2.50% | 4.11% | -2.76× | Reported |
| 2022-06-30 | $3.00M | $110.07M | $4.73M | $-51.62M | $14.58M | 2.72% | 4.30% | -3.54× | Reported |
| 2022-03-31 | $3.28M | $94.00M | $4.35M | $-58.02M | $13.25M | 3.49% | 4.63% | -4.38× | Reported |
| 2021-12-31 | $3.65M | $80.94M | $3.49M | $-58.37M | $13.06M | 4.50% | 4.31% | -4.47× | Reported |
| 2021-09-30 | $3.93M | $68.52M | $2.96M | $-62.40M | $12.85M | 5.74% | 4.32% | -4.86× | Reported |
| 2021-06-30 | $4.87M | $58.11M | $3.05M | $-61.77M | $12.64M | 8.38% | 5.25% | -4.89× | Reported |
| 2021-03-31 | $5.37M | $48.07M | $2.96M | $-63.31M | $12.46M | 11.16% | 6.16% | -5.08× | Reported |
| 2020-12-31 | $5.91M | $42.22M | $2.86M | $-64.91M | $11.99M | 13.99% | 6.76% | -5.42× | Reported |
| 2020-09-30 | $5.36M | $40.30M | $2.80M | $-55.52M | $11.61M | 13.30% | 6.96% | -4.78× | Reported |
| 2020-06-30 | $4.14M | $37.25M | $2.68M | $-50.77M | $11.16M | 11.12% | 7.19% | -4.55× | Reported |
| 2020-03-31 | $3.00M | $36.02M | $2.69M | $-44.99M | $10.17M | 8.33% | 7.47% | -4.42× | Reported |
| 2019-12-31 | $2.34M | $29.35M | $2.65M | $-41.42M | $8.99M | 7.99% | 9.03% | -4.61× | Reported |
| 2019-09-30 | $2.80M | $21.37M | $2.61M | $-50.15M | $7.70M | 13.09% | 12.22% | -6.51× | Reported |
| 2019-06-30 | $3.31M | $18.38M | $2.54M | $-54.89M | $6.45M | 18.00% | 13.81% | -8.50× | Reported |
| 2019-04-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $3.83M | $16.47M | $2.35M | $-56.96M | $5.74M | 23.26% | 14.24% | -9.92× | Reported |
| 2018-12-31 | $3.93M | $16.99M | $2.22M | $-60.29M | $5.52M | 23.11% | 13.09% | -10.92× | Reported |
| 2018-09-30 | $5.94M | (m) | $2.14M | $-54.28M | $5.33M | (m) | (m) | -10.19× | Reported |
| 2018-06-30 | $6.43M | (m) | $2.06M | $-54.92M | $4.71M | (m) | (m) | -11.67× | Reported |
| 2018-03-31 | $6.32M | (m) | $1.84M | $-49.91M | $3.99M | (m) | (m) | -12.51× | Reported |
| 2017-12-31 | $6.23M | (m) | $1.56M | $-39.31M | $3.29M | (m) | (m) | -11.96× | Reported |
| 2017-09-30 | $4.95M | (m) | $1.31M | $-32.71M | $2.67M | (m) | (m) | -12.24× | Reported |
| 2017-06-30 | $4.81M | (m) | $1.06M | $-22.02M | $2.50M | (m) | (m) | -8.83× | Reported |
| 2017-03-31 | $6.85M | (m) | $1.06M | $-19.11M | $2.39M | (m) | (m) | -7.99× | Reported |
| 2016-12-31 | $7.69M | (m) | $1.25M | $-17.33M | $2.24M | (m) | (m) | -7.74× | Reported |
| 2016-09-30 | $9.10M | (m) | $1.49M | $-17.52M | $2.08M | (m) | (m) | -8.44× | Reported |
| 2016-06-30 | $9.54M | (m) | $1.67M | $-18.44M | $1.92M | (m) | (m) | -9.61× | Reported |
| 2016-03-31 | $7.64M | (m) | $1.75M | $-16.47M | $1.83M | (m) | (m) | -8.98× | Reported |
| 2015-12-31 | $7.02M | (m) | $1.71M | $-15.51M | $1.84M | (m) | (m) | -8.42× | Reported |
| 2015-09-30 | $6.94M | (m) | $1.55M | $-15.09M | $1.76M | (m) | (m) | -8.57× | Reported |
| 2015-06-30 | $6.31M | (m) | $1.43M | $-13.47M | $1.65M | (m) | (m) | -8.18× | Reported |
| 2015-03-31 | $6.59M | (m) | $1.40M | $-13.54M | $1.54M | (m) | (m) | -8.82× | Reported |
| 2014-12-31 | $9.52M | (m) | $1.25M | $-16.02M | $1.29M | (m) | (m) | -12.45× | Reported |
| 2014-09-30 | $10.55M | (m) | $1.14M | $-16.83M | $1.07M | (m) | (m) | -15.69× | Reported |
| 2014-06-30 | $10.48M | (m) | $1.04M | $-16.32M | $900.22K | (m) | (m) | -18.13× | Reported |
| 2014-03-31 | $12.17M | (m) | $903.95K | $-17.58M | $716.31K | (m) | (m) | -24.54× | Reported |
| 2013-12-31 | $9.30M | (m) | $888.29K | $-15.04M | $618.23K | (m) | (m) | -24.33× | Reported |
| 2013-09-30 | $7.61M | $3.17M | $884.78K | $-12.76M | $467.02K | 240.46% | 27.94% | -27.33× | Reported |
| 2013-06-30 | $8.15M | $2.42M | $867.75K | $-13.48M | $306.73K | 336.66% | 35.86% | -43.95× | Reported |
| 2013-03-31 | $4.85M | $1.91M | $799.08K | $-9.85M | $150.99K | 254.63% | 41.91% | -65.21× | Reported |
| 2012-12-31 | $3.47M | $1.12M | $626.79K | $-7.91M | $30.68K | 310.26% | 56.06% | -257.77× | Reported |
| 2012-12-19 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $646.76K | $761.04K | $22.95K | $-4.62M | $1.60M | 84.98% | 3.02% | -2.88× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |